Healthcare

Q2 2019 Deals Industry Insights: Megadeals in many sectors reflect interest in increasing scale

By  John Potter, US Deals Sector Leader @johndpotter Anyone who says summer is slow for business isn’t watching M&A, and …

Global pharma and life sciences deals insights: Year-end 2018

A year end look at M&A in the Pharmaceutical and Life Sciences sector, and new deals setting the stage for a strong start to 2019.   By Glenn …

PwC Deals in the AIRA Journal

For years, Long-Term Acute Care Hospitals (LTACHs) have been at the center of a transformation of how healthcare providers care for patients and are reimbursed for services. Now, as new patient care …

How the FASB’s new definition of a business impacts pharma/life sciences deals

By Shurjo Sen, PwC Deals Partner, Accounting Advisory In January 2017, the Financial Accounting Standards Board (FASB) issued new guidance …

Restructuring trends: What did we see in 2017 and what lies ahead for 2018?

By Steve Fleming, US Crisis and Restructuring Leader, PwC Deals In our recently released paper, Bankruptcy and Restructuring: 2017 in Review and …

Capturing deal value in Healthcare Services

By Angus Buchanan, Principal, PwC’s Deals Practice It’s no secret the healthcare market has undergone a wave of M&A activity over the past decade as service providers …

PwC’s Mid-year Deals Outlook: Slow start, but still active

Can we expect a dealmaking turnaround in 2016? Dealmaking significantly subsided in the first half of 2016 following a very active year. Equity market volatility, …

Contacts

Colin Wittmer

Deals Leader, PwC US Email

Curt Moldenhauer

Deals Solutions Leader, PwC US Tel: +1 (408) 817 5726 Email: curt.moldenhauer@pwc.com